Mer­ri­mack Phar­ma’s stock plunges (again) on its lat­est can­cer drug tri­al flop

Mer­ri­mack Phar­ma­ceu­ti­cals $MACK has an­oth­er los­er on its hands.

The drug MM-121 (serib­an­tum­ab) added to do­c­etax­el did not do any bet­ter than do­c­etax­el alone in im­prov­ing the pro­gres­sion-free sur­vival of pa­tients suf­fer­ing from non-small cell lung can­cer.

Mer­ri­mack’s stock, al­ready blight­ed by tri­al fail­ure, quick­ly plunged anew, drop­ping more than 30% on the lat­est set­back. The stock was trad­ing at around $3.50 mid-morn­ing. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.